Dexamethasone metasulfobenzoate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Dexamethasone metasulfobenzoate is an ophthalmic and auricular corticosteroid used with antibiotics for the treatment of otitis externa, blepharitis, and other inflammatory eye conditions.
- Brand Names
- Sofracort
- Generic Name
- Dexamethasone metasulfobenzoate
- DrugBank Accession Number
- DB14703
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
- Weight
- Average: 576.63
Monoisotopic: 576.18293198 - Chemical Formula
- C29H33FO9S
- Synonyms
- Dexamethasone m-sulfobenzoate
- Dexamethasone-21-sulfobenzoate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Dexamethasone sodium metasulfobenzoate 4T1RAI19H8 3936-02-5 RPBJOYICBFNIMN-RDWMNNCQSA-M - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image POLYDEXA EAR DROPS Dexamethasone sodium metasulfobenzoate (0.1 g/100ml) + Neomycin sulfate (650000 iu/100ml) + Polymyxin B sulfate (1000000 iu/100ml) Solution Auricular (otic) PHARMACON PTE LTD 1990-07-16 Not applicable Singapore Sandoz Opticort Dexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL) Solution Auricular (otic); Ophthalmic Sandoz Canada Incorporated 2004-01-16 2019-08-01 Canada Sofracort Dexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL) Solution / drops Auricular (otic); Ophthalmic Sanofi Aventis 2002-07-26 Not applicable Canada Sofracort Eye/ear Drops Dexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL) Solution / drops Auricular (otic); Ophthalmic Roussel Canada Inc. 1966-12-31 1996-09-09 Canada Sofracort Sterile Ear/eye Drops Dexamethasone sodium metasulfobenzoate (0.5 mg / mL) + Framycetin sulfate (5 mg / mL) + Gramicidin D (0.05 mg / mL) Solution / drops Topical Hoechst Roussel Canada Inc. 1966-12-31 2004-07-30 Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- C67221CB9Q
- CAS number
- 16978-57-7
- InChI Key
- TWQWRHIQRAZHPR-XNXCGYEVSA-N
- InChI
- InChI=1S/C29H33FO9S/c1-16-11-22-21-8-7-18-13-19(31)9-10-26(18,2)28(21,30)23(32)14-27(22,3)29(16,35)24(33)15-39-25(34)17-5-4-6-20(12-17)40(36,37)38/h4-6,9-10,12-13,16,21-23,32,35H,7-8,11,14-15H2,1-3H3,(H,36,37,38)/t16-,21+,22+,23+,26+,27+,28+,29+/m1/s1
- IUPAC Name
- 3-({2-[(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-fluoro-1,10-dihydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}carbonyl)benzene-1-sulfonic acid
- SMILES
- [H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C3=CC=CC(=C3)S(O)(=O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- General References
- Not Available
- External Links
- ChemSpider
- 56740
- ChEMBL
- CHEMBL3305965
- ZINC
- ZINC000004212887
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Treatment Anesthetics Adverse Reaction / Hemodynamics Instability / Nausea / Paralytic Ileus / Postoperative pain / Vomiting 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Auricular (otic) 0.1 g/100ml Solution Auricular (otic); Ophthalmic Solution / drops Auricular (otic); Ophthalmic Solution / drops Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0457 mg/mL ALOGPS logP 1.87 ALOGPS logP 1.22 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) -2.5 Chemaxon pKa (Strongest Basic) -3.4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 155.27 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 142.94 m3·mol-1 Chemaxon Polarizability 57.93 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 21, 2018 14:26 / Updated at June 12, 2020 16:53